Physician profile
Jonathan P Castro
NPI 1093709479
$3,489.17
in general payments reported to CMS, 2019-2025
31 companies · $584 in 2025
The $584 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,020 · 2020: $439 · 2021: $420 · 2022: $208 · 2023: $573 · 2024: $247 · 2025: $584.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,318 · Education: $84.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,318.30 |
| Education | $84.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $849.40 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $286.44 | 2019-2025 | Mounjaro, Jardiance, Baqsimi |
| Insulet Corporation | $215.09 | 2019-2025 | Omnipod |
| Boehringer Ingelheim Pharmaceuticals, INC. | $186.69 | 2019-2024 | Tradjenta, Synjardy, Jardiance |
| Medtronic Minimed, INC. | $181.13 | 2020 | |
| Antares Pharma, INC. | $173.93 | 2019-2024 | Xyosted, Nocdurna, Tlando |
| Sanofi-Aventis U.S. LLC | $154.21 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $140.97 | 2019-2025 | Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $138.27 | 2021-2024 | |
| Abbott Laboratories | $108.52 | 2019-2025 | Freestyle Libre |
| Medtronic, INC. | $100.29 | 2021-2025 | Minimed 780g |
| Abbvie INC. | $93.39 | 2019-2025 | |
| Medline Industries LP | $86.15 | 2024 | Medline |
| Astellas Pharma US INC | $84.99 | 2023 | |
| Tandem Diabetes Care, INC. | $73.33 | 2022-2025 | T:Slim X2 Insulin Pump With Control-Iq |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $68.64 | 2019 | |
| Amgen INC. | $58.58 | 2019 | |
| Sequel Med Tech, LLC | $50.35 | 2025 | Twiist |
| Xeris Pharmaceuticals, INC. | $49.05 | 2025 | Recorlev |
| Amneal Pharmaceuticals LLC | $48.19 | 2021-2025 | Unithroid |
| Dexcom, INC. | $43.48 | 2022-2025 | Dexcom G6 Transmitter |
| Pfizer INC. | $42.28 | 2019-2020 | |
| Ascendis Pharma Endocrinology INC | $40.67 | 2025 | Yorvipath |
| Amarin Pharma, INC. | $38.07 | 2019 | |
| Janssen Pharmaceuticals, INC | $36.96 | 2019 | |
| Beta Bionics, INC. | $28.94 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Embecta Corp. | $26.70 | 2023 | Bd Nano 2nd Gen Pen Needle |
| Rhythm Pharmaceuticals, INC. | $24.25 | 2025 | Imcivree |
| Novartis Pharmaceuticals Corporation | $23.58 | 2025 | |
| Clarus Therapeutics INC. | $22.65 | 2021 | |
| Ibsa Pharma INC. | $13.98 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Castro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.